IGES sets up a new subsidiary in France – IGES France Pharma Consulting

Continuation of its European growth course – Expansion of the services for pharmaceutical companies in Europe

Berlin, 11. October 2023 (IGES Institute) – The IGES Group continues to grow and has set up a new subsidiary in France. IGES France Pharma Consulting proposes strategic and health economics consulting services for the developers and manufacturers of medicinal products seeking to place products on the French and European markets.

The new company is embedded in the existing, comprehensive Europe-wide service network of the IGES Group for the life sciences industry. The Group has subsidiaries in six European countries and provides consulting on the market launch and pricing of medical innovations. In 2022, IGES UK Pharma Consulting was established to provide parallel services for the United Kingdom.

"France is the second largest pharmaceutical market in Europe after Germany and an important country of entry for the innovations of pharmaceutical companies. With IGES France Pharma Consulting, we can now also cover the French market within the framework of European launch projects", says Professor Bertram Häussler, Head of the IGES Group.

Häussler is also the CEO of IGES France Pharma Consulting. Pierre Moïse joins IGES France Pharma from the Consulting Services arm of IQVIA as its operational director. Moïse is an economist and has worked for more than 20 years in international companies and organisations as a life sciences consultant. His focus is on market access issues and international health and research policy developments.

IGES Institute – The knowledge corporation: from information to innovation

Founded in Berlin in 1980, the IGES Institute is the heart of the IGES Group. Today, it is one of the largest private sector research and consulting companies for infrastructure and health issues in Germany. Since its inception, it has worked on more than 4,000 projects on issues related to access to care, quality of care, financing and the shaping of competition in the field of health. In addition to the IGES Institute, the IGES Group encompasses several specialist subsidiaries in six European countries that primarily provide services to international life sciences industries. The Group has a staff of more than 200 highly qualified individuals.

IGES France Pharma Consulting

IGES France Pharma Consulting is a Paris-based consulting and services company for drug developers and manufacturers. It provides market launch and reimbursement support for novel pharmaceutical developments in France and in Europe. IGES France Pharma Consulting is part of the IGES Group that operates a network of subsidiaries for the international life science industries in six European countries.

Panel at BIO-EUROPE: Start early, seek advice, talk to the HTA Agencies
EU-HTA will start in time in 69 days. Fundamental implementing acts adopted – preparations under time pressure but will finish in time.
IGES Pharma at BIO Japan 2024
IGES Pharma is taking part in the BIO Japan 2024 convention, the second largest industry event of its kind for the biopharmaceutical sector. The focus is on dialogue with innovative Asian biopharmaceutical companies on market access and reimbursement in Europe.
Santoke Naal from IGES at the BIO 2024 International Convention: "It is important to engage much earlier with the HTA-Agencies than before.”
The panel “Europe's Policy Environment and the Impact on the Biotech Sector” analyzed the proposed revisions to the General Pharmaceutical Legislation (GPL) , including changes to regulatory data protection.
Expert discussion with IGES: Focus on transatlantic cooperation in the biotech sector
The world's largest biotech congress of its kind, the BIO International Convention, has a strong European focus this year. With the participation of the IGES Group, it brings together major European pharmaceutical and biotech stakeholders to discuss the latest changes in EU legislation and their consequences for the transatlantic pharmaceutical market. The congress will be held in San Diego, California, from 3 to 6 June. More than 20,000 visitors are expected to attend.
IGES Group with HTA experts at BIO-Europe Spring 2024
The IGES Group is once again taking part in BIO-Europe Spring, one of the largest trade fairs of its kind for the life sciences sector in Europe. The main focus will be on the exchange of information on the European Health Technology Assessment (HTA) procedure, EU-HTA.
Current documents on the EU-HTA process and opportunity to provide feedback
On March 5, 2024 the draft implementing regulation was published for public consultation on the “have your say” homepage of the EU – and is open for feedback for four weeks until 02 April 2024.
12 January 2025 - The Countdown runs
Pharmaceuticals and medical devices - the countdown runs! January 12, 2025, the era of national product assessments ends and the application of the EU HTA Regulation begins.
IGES Life Science at the health economics conference ISPOR Europe 2023
The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on orphan drugs. ISPOR Europe 2023 will take place from November 12 to 15 in Copenhagen.
EU HTA harmonisation under time pressure: discussion at the biotech congress "BIO Europe 2023"
The time pressure due to EU HTA harmonisation is growing. In less than 15 months, the first medicinal products must undergo a central, EU-wide clinical evaluation procedure. The procedure itself is also taking place under high time pressure - with very tight deadlines and largely parallel to the marketing authorisation. What companies should urgently do now to successfully bring their new developments through the procedure is the topic of an IGES expert event at BIO Europe 2023 on 07 November in Munich.
IGES sets up a new subsidiary in France – IGES France Pharma Consulting
Continuation of its European growth course – Expansion of the services for pharmaceutical companies in Europe
IGES acquires majority stake in Synergus RWE – a European Medtech market access specialist
Continuation of its European growth course – Expansion of services for manufacturers of medical devices - Integration of the use of Scandinavian medical registries

Bringing Innovations to European Patients

IGES sets up a new subsidiary in France – IGES France Pharma Consulting